Navigation Links
Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
Date:2/19/2013

PARSIPPANY, N.J., Feb. 19, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT) today reported net revenue increased 13 percent to $1.75 billion for the fourth quarter 2012, compared to $1.54 billion in the fourth quarter 2011. On a non-GAAP basis, diluted earnings per share for the fourth quarter 2012 was $1.59, compared to $1.77 per diluted share in the fourth quarter 2011, a decline of 10%.  GAAP earnings per diluted share for the fourth quarter 2012 were $0.21, compared to $0.75 in the prior year period. Fourth quarter 2011 earnings includes the launch of generic Lipitor® which contributed $0.64 of non-GAAP earnings per diluted share to the prior-year period compared to $0.03 in the fourth quarter of 2012. 

For the fourth quarter 2012, adjusted EBITDA was $393.0 million, compared to $393.4 million for the fourth quarter 2011.
Cash and marketable securities were $328.0 million as of December 31, 2012.

For the full year 2012, net revenue increased 29 percent to $5.9 billion, compared to net revenue of $4.6 billion for full year 2011.  On a non-GAAP basis, 2012 earnings per diluted share increased 26% to $6.00 per diluted share compared $4.77 per diluted share in 2011. GAAP earnings per diluted share were $0.76 for the full year 2012, compared to $2.06 in 2011. Adjusted EBITDA for the full year 2012 increased 26 percent to $1.4 billion, compared to full year 2011 adjusted EBITDA of $1.1 billion. Cash flow from operations was $665.8 million.

Fourth quarter and full year 2012 results for Actavis, Inc. include results of legacy Actavis as of November 1, 2012. Refer to the attached reconciliation tables for adjustments to GAAP earnings.

"With the close of the Actavis acquisition and combination of our two companies, under our new global name, Actavis, Inc., we are beginning 2013 on a solid commercial and financial foundation, well-pos
'/>"/>

SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Watson to Acquire Actavis Group for EUR4.25 Billion
2. Actavis Launches First Generic Equivalent of Requip® XL (Ropinirole Extended-Release Tablets)
3. Actavis Launches Generic Equivalent of Adalat® CC 90mg (Nifedipine Extended-Release Tablets, USP)
4. Watson and Actavis Receive FTC Second Request
5. Watson Announces New Name -- Actavis -- for Global Operations
6. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
7. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
8. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
9. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
10. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
11. Aethlon Medical Note: Fiscal Year Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... DIEGO, July 29, 2014  Sequenom, Inc. (NASDAQ: ... genetic analysis solutions, today reported total revenues of $39.8 ... of 62% compared to revenues of $24.5 million for ... Bioscience business segment, which was sold on May 30, ... and consequently its results have been excluded from continuing ...
(Date:7/29/2014)... MOUNTAIN VIEW, Calif. , July 29, 2014 /PRNewswire/ ... today that it is participating in two healthcare conferences ... 1-1 Conference and the Morgan Stanley Global Healthcare 2014 ... the Morgan Stanley Conference.  The details on each event ... 1-1 Conference, Monday, August 11, 2014 in ...
(Date:7/29/2014)... Edwards Lifesciences Corporation (NYSE: EW ), ... hemodynamic monitoring, today reported net income for the quarter ended ... share, and non-GAAP net income of $94.0 million, or $0.88 ... year earlier was $93.3 million, or $0.81 per diluted share, ... diluted share.  Net sales for the quarter ...
Breaking Medicine Technology:Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 2Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 3Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 4Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 5Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 6Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 7Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 8Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 9Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 10Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 11Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 12Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 13Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 14Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 15Sequenom, Inc. Reports Financial Results For The Second Quarter Of 2014 16Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 2Alexza Pharmaceuticals Announces Participation in Upcoming Investor Conferences 3Edwards Lifesciences Reports Strong Second Quarter Results 2Edwards Lifesciences Reports Strong Second Quarter Results 3Edwards Lifesciences Reports Strong Second Quarter Results 4Edwards Lifesciences Reports Strong Second Quarter Results 5Edwards Lifesciences Reports Strong Second Quarter Results 6Edwards Lifesciences Reports Strong Second Quarter Results 7Edwards Lifesciences Reports Strong Second Quarter Results 8Edwards Lifesciences Reports Strong Second Quarter Results 9Edwards Lifesciences Reports Strong Second Quarter Results 10Edwards Lifesciences Reports Strong Second Quarter Results 11Edwards Lifesciences Reports Strong Second Quarter Results 12Edwards Lifesciences Reports Strong Second Quarter Results 13Edwards Lifesciences Reports Strong Second Quarter Results 14Edwards Lifesciences Reports Strong Second Quarter Results 15Edwards Lifesciences Reports Strong Second Quarter Results 16Edwards Lifesciences Reports Strong Second Quarter Results 17Edwards Lifesciences Reports Strong Second Quarter Results 18Edwards Lifesciences Reports Strong Second Quarter Results 19
... Mass., Feb. 15, 2011 Echo Therapeutics, Inc. (OTC ... the Symphony™ tCGM System as a non-invasive, wireless, transdermal ... System for transdermal drug delivery, today announced the appointment ... its Board of Directors.  Echo,s Board now has a ...
... Sanofi-aventis (EURONEXT: SAN and NYSE: ... announced that they have entered into a research agreement ... treat chronic wounds. This includes neuropathic diabetic foot ulcers ... that are complicated by peripheral arterial disease, commonly called ...
Cached Medicine Technology:Echo Therapeutics Announces Appointments to Board of Directors 2Echo Therapeutics Announces Appointments to Board of Directors 3Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 2Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 3Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers 4
(Date:7/29/2014)... The Natural Multiple Sclerosis Treatment review ... to Gary M. Levin’s cure program. , Levin ... this serious disorder. Levin says that multiple sclerosis actually ... be found in patients. , Dr. Gary M. ... years, Levin has worked with patients suffering from MS. ...
(Date:7/29/2014)... 2014 Winter is here down under, ... in Sydney’s central business district. That is, until a ... transformed the otherwise ordinary day into a celebration—a celebration ... ardent advocates of The Truth About Drugs, a drug ... . They woke up the city with a rousing ...
(Date:7/29/2014)... Daily Gossip reveals in its review that ... that will permanently eliminate all the symptoms associated to this ... will banish symptoms such as mild hearing loss, as well ... patients will be gone forever. , The method will lead ... of this program says that at the end of the ...
(Date:7/29/2014)... --,The time at which heart attack patients arrive at ... research suggests. Showing up at the emergency room ... with a 13 percent higher risk for death than ... year, more than 250,000 people suffer a ST-elevation myocardial ... which is caused by a complete blockage of blood ...
(Date:7/29/2014)... 29, 2014 (HealthDay News) -- Although the bite of ... heal well if left alone, an expert notes. ... an adverse reaction to a brown recluse spider bite, ... Poison Center, particularly since these potentially dangerous bites are ... for us to do nothing. The [bite] has classic ...
Breaking Medicine News(10 mins):Health News:Natural Multiple Sclerosis Treatment Review Reveals the Inside Story to Gary M. Levin’s Cure Program 2Health News:Sydney Business District “Rocked” by The Truth About Drugs 2Health News:Tinnitus Miracle Review Exposes the Only Holistic System for Tinnitus Cure 2Health News:Heart Attack Patients Treated at Night, Weekends May Have Worse Outcomes 2Health News:Brown Recluse Spider Bites on the Rise, Expert Warns 2
... regulators told a Congressional panel today that some biological ... -- are simple enough// to produce in generic versions, ... ,Generic versions of certain biologics have been ... approval came only after manufacturers conducted rigorous human clinical ...
... of governments of Western Pacific countries in fighting tuberculosis (TB), ... control the disease. ,The region has successfully met ... of TB cases and curing at least 85 percent of ... body's TB programme. ,He was speaking at a ...
... Researchers from the decades long Framingham Heart Study, say that if ... there is a good chance// of you having lessened the risk ... continue, if your parents died young, diet and exercise may well ... published in the Archives of Internal Medicine, show that middle-aged children ...
... of industrial chemicals has suggested that we may not ... prolonged use of non-stick frying// pans and baking trays; ... penetrate into our system causing health problems, they said. ... Notification and Assessment Scheme or NICNAS said it is ...
... mattresses and TVs contain possibly hazardous chemicals called polybrominated ... National Institute of Standards and Technology and the Environmental ... ,It is not yet clear how dangerous these PBDEs ... of Europe. Their structure is strikingly similar to that ...
... soldiers who are suffering from mental illness after serving ... 18 months or longer for treatment// from the National ... figures released by British Ministry of Defence (MoD) showed ... health conditions after returning from Iraq since 2003. More ...
Cached Medicine News:Health News:Caution Urged on Biologic Drugs 2Health News:WHO Calls for Greater Efforts to Fight TB 2Health News:Take Heart If Your Parents Died at a Ripe Old Age: Framingham Heart Study 2
Provides the security of suture and ease of automated knot tying for vascular closure of 5-8F....
... The all-new Canon CF-60DSi is an all-digital ... simple configuration, and an efficient workflow. ... mounts -- The Canon EOS-1Ds series SLR digital ... a 11.1 mega pixel resolution and the new ...
... The AIA-360 is a sophisticated Aumated Immunoassay ... This analyzer has a footprint of 16 X ... lbs. Its compact design is ideal for ... STAT testing, such as cardiac panels, as well ...
... a simple one, help physicians serve their ... the physician is provided with significantly useful ... This technical accomplishment is combined with dedicated ... The device features: High ...
Medicine Products: